Nafagrel

Drug Profile

Nafagrel

Alternative Names: DP 1904; SR 96325

Latest Information Update: 19 Dec 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Daiichi Pharmaceutical; Sanofi-Synthelabo
  • Class Anti-ischaemics; Antiplatelets; Imidazoles; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Asthma; Diabetic angiopathies; Heart failure; Raynaud's disease

Most Recent Events

  • 19 Dec 2000 Discontinued-Clinical for Raynaud's disease in Japan (PO)
  • 19 Dec 2000 Discontinued-Unspecified phase in Diabetic angiopathies in Japan (Unknown route)
  • 19 Dec 2000 Discontinued-Unspecified phase in Heart failure in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top